The Senate confirmed Dr. Erica Schwartz as director of the Centers for Disease Control and Prevention (CDC) in a 51-44 vote on Wednesday, marking the agency’s first confirmed leadership appointment in nearly a year. Schwartz, 54, assumes command of the Atlanta-based public health institution amid ongoing challenges, including political interference and significant staff losses.
Schwartz brings a diverse background to the CDC, holding both medical and law degrees. Her experience includes serving as deputy surgeon general and holding a leadership position within the U.S. Coast Guard. Despite initial skepticism during her April nomination and Senate hearings, she gained bipartisan support following discussions with senators, including Sen. Bill Cassidy (R-La.), who expressed confidence in her leadership ability. Concerns had been raised about whether she would resist directives from Health Secretary Robert F. Kennedy Jr. that might undermine science-based public health guidance.
The CDC has experienced considerable turmoil since the start of the current presidential administration, losing more than 3,000 employees—over one-quarter of its workforce—to layoffs and resignations. Morale has suffered as the agency cycled through a series of temporary leaders and political appointees with limited expertise in medicine or public health.
Recent years have seen frequent leadership vacancies at the CDC. Schwartz is the third nominee for the director role proposed by the administration in the past 18 months. Her predecessors in the nomination process included Dr. David Weldon, a former Florida congressman whose Senate hearing was canceled shortly before it was to begin, and Susan Monarez, a former acting CDC director who was confirmed but removed from the role within a month due to reported misalignment with the administration’s agenda.
Public health advocates have stressed the need for stability and science-driven leadership at the CDC. The National Public Health Coalition, comprising former and current CDC employees, emphasized the importance of a director who will prioritize evidence-based guidance and safeguard public health workers from political pressures. Similarly, Dr. Georges Benjamin of the American Public Health Association underscored the agency’s urgent requirement for experienced leadership committed to scientific integrity.
Officials from the Department of Health and Human Services have yet to announce details regarding Schwartz’s start date and salary. Schwartz’s appointment arrives amid continued leadership gaps across several federal health agencies, including the offices of the U.S. surgeon general and the Food and Drug Administration commissioner.